Deals this week: Zealand Pharma, Fulcrum Therapeutics, Forendo Pharma

14th September 2018 (Last Updated September 14th, 2018 00:00)

Zealand Pharma has sold its future royalty streams and potential commercial milestones for Soliqua® 100/33/Suliqua® and Lyxumia®/Adlyxin® to Royalty Pharma for $205m.

Zealand Pharma has sold its future royalty streams and potential commercial milestones for Soliqua® 100/33/Suliqua® and Lyxumia®/Adlyxin® to Royalty Pharma for $205m.

Based in Denmark, Zealand Pharma specialises in the discovery and development of peptide therapeutics-based medicines, while Royalty Pharma is a US-based firm that invests in pharmaceutical and biopharmaceutical products.

The transaction will generate the required funds for the development of Zealand Pharma’s product pipeline.

Morgan Stanley & Co. has been appointed as the sole structuring agent for the asset transaction.

Fulcrum Therapeutics has raised $80m in a series B financing round from Foresite Capital, a private equity investment firm based in the UK.

The funding round also included participation from other investors such as Fidelity, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments, entities affiliated with Leerink Partners, and other undisclosed institutional investors.

Based in the US, Fulcrum Therapeutics is a biopharmaceutical company engaged in the development of drugs for transforming gene regulation in disease.

The company plans to use the funds for the clinical development of its lead programme in facioscapulohumeral muscular dystrophy (FSHD) and to further support its rare disease-focused product pipeline.

"Fulcrum Therapeutics has raised $80m in a series B financing round from Foresite Capital, a private equity investment firm based in the UK."

Forendo Pharma has raised €4m ($4.6m) from Vesalius Biocapital III Partners (Vesalius III).

The company previously raised €12m ($14.5m) through a series A financing round in 2014.

Based in Finland, Forendo Pharma is a drug discovery and development company that focuses on tissue-specific hormone mechanisms.

The company plans to use the funds for the development of its women's health portfolio.

Twentyeight-Seven Therapeutics has raised $65m through a series A financing round from founding investor MPM Capital. The financing round was co-led by Novartis Venture Fund.

Additional investors such as Johnson & Johnson Innovation - JJDC, Vertex Ventures HC, Longwood Fund, and Astellas Venture Management also participated in the funding round.

Based in the US, Twentyeight-Seven Therapeutics is a biotechnology company engaged in the development of small molecules that can modulate levels of miRNAs, to treat cancer and other human diseases.

The company plans to use the funds for the development of its lead programme Let-7, a microRNA (miRNA) suppressor used for cancer treatment.